Krystal Biotech Inc (KRYS, Financial) is set to release its Q3 2024 earnings on Nov 4, 2024. The consensus estimate for Q3 2024 revenue is $82.95 million, and the earnings are expected to come in at $0.89 per share. The full year 2024's revenue is expected to be $291.81 million and the earnings are expected to be $2.62 per share. More detailed estimate data can be found on the Forecast page.
Krystal Biotech Inc (KRYS, Financial) Estimate Trends
Over the past 90 days, revenue estimates for Krystal Biotech Inc (KRYS) for the full year 2024 have increased from $267.11 million to $291.81 million, and for 2025 from $419.9 million to $477.95 million. Similarly, earnings estimates have risen from $2.16 per share to $2.62 per share for 2024, and from $4.95 per share to $5.73 per share for 2025.
Krystal Biotech Inc (KRYS, Financial) Reported History
In the previous quarter of June 30, 2024, Krystal Biotech Inc's (KRYS) actual revenue was $70.28 million, which beat analysts' revenue expectations of $65.335 million by 7.57%. Krystal Biotech Inc's (KRYS) actual earnings were $0.53 per share, which met analysts' earnings expectations. After releasing the results, Krystal Biotech Inc (KRYS) was down by -5.85% in one day.
Krystal Biotech Inc (KRYS, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 9 analysts, the average target price for Krystal Biotech Inc (KRYS) is $207.22 with a high estimate of $221 and a low estimate of $193. The average target implies an upside of 20.15% from the current price of $172.47.
Based on GuruFocus estimates, the estimated GF Value for Krystal Biotech Inc (KRYS, Financial) in one year is $0, suggesting a downside of -100% from the current price of $172.47.
Based on the consensus recommendation from 11 brokerage firms, Krystal Biotech Inc's (KRYS, Financial) average brokerage recommendation is currently 1.7, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
